Novo's Worst Year Is Your Best Opportunity

Analyst rates Novo Nordisk a Buy, arguing the market has over‑discounted the company after a difficult 2025 'peak pain' year marked by political pricing risk, pricing pressure on Wegovy, previous guidance cuts tied to next‑generation obesity program issues and a management reshuffle; the firm is booking roughly DKK 9 billion of restructuring and impairment charges in 2025 while targeting about DKK 8 billion of annual savings by 2026. Q3 results showed revenues up 12.47% YoY but missed consensus by 2.72%, EPS beat consensus (~13.2%) yet fell 21.6% YoY, and adjusted operating profit rose 16% in DKK (21% at constant currency) once one‑offs are excluded — supporting the view that underlying growth remains solid. Key catalysts cited are FDA priority review of an oral Wegovy (which could materially lower COGS and accelerate volume), a deepening metabolic pipeline including CagriSema (Phase 3, potential 2026 filing) and M&A (Akero ~$5.2bn, Cardior up to ~$1.1bn); the analyst models a mid‑cycle P/E recovery to 15–16x by end‑2026 and a 12‑month target of ~$56.3 (~15% upside), while flagging execution risk, sustained competition from Eli Lilly and the prospect of further earnings revisions as primary downside risks.

Analysis

Q3 2025 results show revenue growth of 12.47% year‑over‑year but a 2.72% miss to consensus, while EPS beat consensus by roughly 13.21% yet declined 21.59% YoY in USD; management booked about DKK 9 billion of restructuring and asset‑impairment charges in 2025, creating what the analyst terms a “peak pain” year. Adjusted operating profit rose 16% in Danish kroner (21% at constant currency) once one‑offs are excluded, indicating underlying volume growth despite near‑term margin pressure.

Management is targeting roughly DKK 8 billion of annual savings by ~2026, which the analyst believes can offset much of the 2025 write‑downs if executed; Q3 gross margin was slightly above 81% and could fall toward 70% but be recovered over time through cost actions and scale. Oral Wegovy is under FDA priority review and, if approved and launched across traditional and telehealth/retail channels, could materially lower COGS and accelerate market penetration by shifting volume to tablet manufacturing.

Novo is extending its metabolic franchise via M&A (Akero for ~$5.2bn; Cardior up to ~$1.1bn) and a Phase‑3 CagriSema program with a potential 2026 filing; the analyst models a mid‑cycle P/E recovery to 15–16x by end‑2026 and a 12‑month target of $56.3 (~15% upside). Key downside risks that could prevent this recovery are execution of the new management’s cost plan, further earnings revisions, and continued competitive share gains by Eli Lilly and other GLP‑1 players.

Key Decisions for Investors

• Consider a modest buy/add to positions given a projected ~15% 12‑month upside to $56.3, but size exposure conservatively because upside is capped and execution risk is material
• Monitor three hard catalysts—FDA priority review outcome for oral Wegovy, realization of DKK 8bn annual savings in 2026, and regulatory progress on CagriSema—and materially reprice exposure if any are missed
• Use staged entries or protective hedges (e.g., collars or puts) to limit downside from additional earnings revisions or further US pricing/policy shocks
• Avoid concentration versus Eli Lilly exposure; if competition continues to out‑execute, rotate into better performing GLP‑1 franchises or trim NVO exposure